Burning Rock Biotech Ltd Stock Price, News & Analysis

Burning Rock Biotech Limited (NASDAQ: BNR) has partnered with IMPACT Therapeutics to advance companion diagnostics (CDx) for the PARP inhibitor Senaparib, targeting prostate cancer. The partnership aims for global CDx submissions to the FDA and NMPA, leveraging Burning Rock's accredited labs in China and California. Senaparib is currently undergoing multiple clinical trials, including a Phase III trial for metastatic castration-resistant prostate cancer (mCRPC). This collaboration is expected to expedite clinical research, benefiting patients worldwide.

Burning Rock Biotech Limited (NASDAQ: BNR) will release its unaudited financial results for Q2 2021 on August 31, 2021, before the U.S. market opens. A conference call will follow at 8:00 a.m. ET to discuss the results. The company specializes in next-generation sequencing (NGS) technology for precision oncology, having completed over 273,000 tests. Burning Rock's focus includes NGS-based therapy selection and cancer early detection, which is in the clinical validation stage. Investors can access earnings results on their investor relations website.

Burning Rock Biotech (NASDAQ: BNR) reported Q1 2021 revenues of RMB106.6 million (US$16.3 million), up 58.4% from Q1 2020, but down 19.1% sequentially due to COVID-19 and seasonal impacts. Their central laboratory revenue rose 61.6% to RMB74.6 million (US$11.4 million), driven by a 64.9% increase in patient tests. However, net loss expanded to RMB171.4 million (US$26.2 million) from RMB52.6 million in Q1 2020. The company forecasts 2021 revenues at approximately RMB610 million (US$93.1 million), indicating 41.9% growth from 2020.

Burning Rock Biotech Limited (NASDAQ: BNR) has launched the PRESCIENT study, the first blood-based pan-cancer early-detection initiative in China using a multi-omics approach. This groundbreaking study will enroll 11,879 participants across 22 cancer types. The project aims to enhance the efficiency of cancer detection through liquid biopsy, promising improved patient outcomes. The study is backed by prominent experts from the National Cancer Center, who emphasize the necessity of advancing early detection technology in China to address rising cancer incidence and to provide clinical evidence for effective diagnostic tools.

Burning Rock Biotech Limited (NASDAQ: BNR) has announced its inclusion in the MSCI China Index effective May 27, 2021. This recognition positions Burning Rock as the only NGS-based precision oncology company from China included in the current MSCI semi-annual index review. The company's mission emphasizes the use of next generation sequencing technology to enhance precision oncology, with significant activities in therapy selection testing and cancer early detection.

Burning Rock Biotech Limited (NASDAQ: BNR) announced a partnership with Abbisko Therapeutics to develop a companion diagnostic (CDx) assay for ABSK091, aimed at detecting FGFR genetic alterations in urothelial carcinoma patients. Prior studies indicated that ABSK091, an FGFR inhibitor, exhibited safety and preliminary efficacy. Abbisko has received IND approval for ABSK091 from the NMPA and plans to initiate phase Ib/II clinical trials in China. This collaboration aims to leverage next-generation sequencing technology to enhance oncology drug development.

Burning Rock Biotech Limited (NASDAQ: BNR) is set to release its unaudited financial results for Q1 2021 on May 25, 2021, before U.S. market opens. The company will hold a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) the same day to discuss these results. Burning Rock focuses on next generation sequencing (NGS) technology in precision oncology, leading the market in China with over 273,000 completed tests. More details will be available on their investor relations website.

Burning Rock Biotech (NASDAQ: BNR) announced strong results from its liquid biopsy assay, recognized in the FDA-led SEQC2 study published in Nature Biotechnology. The assay achieved superior accuracy, sensitivity, and the lowest false-positive rate among five industry-leading ctDNA assays, highlighting its potential in cancer monitoring. With a sensitivity above 90% at low variant allele frequencies (0.3-0.5%), Burning Rock aims to enhance precision oncology solutions. The assay's high performance positions the company favorably within the rapidly evolving NGS-based ctDNA testing market.

Burning Rock Biotech Limited (NASDAQ: BNR) reported its financial results for Q4 and full year 2020, highlighting a 48.5% revenue increase to RMB131.7 million (US$20.2 million) despite COVID-19 impacts. Full year revenues reached RMB429.9 million (US$65.9 million), a 12.6% rise from 2019. The central laboratory business grew by 22.5% year-over-year. However, the company reported a net loss of RMB156.5 million (US$24.0 million) for Q4 and a total loss of RMB407.2 million (US$62.4 million) for 2020. For 2021, Burning Rock anticipates revenues of approximately RMB610 million (US$93.5 million), indicating 41.9% growth.